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Objectives: Little is known about Clostridium difﬁcile (CD) in CF.
Methods: Using culture-based methods we examined prevalence, ribotype and
toxigenic capability of CD in the gut of asymptomatic adult CF patients attending
our centre who donated a stool sample. Results were correlated with clinical
parameters and a same-site healthy volunteer group.
Conclusion: 50 patients have been recruited to date: 58% (n = 29) male, 82%
(n = 41) pancreatic insufﬁcient, 72% (n = 36) class 1−3 mutation, mean age 30.1
(SD ±12.3 years) and mean FEV1 61.3 (SD ±25.1% predicted). 78% (n = 39) were
receiving macrolide therapy and 48% (n = 24) taking a proton pump inhibitor (PPI).
CD was detected in 50% (n = 25) of patients and 2% (n = 2) of healthy controls.
60% of patients (n = 15) were toxin positive, with 14 positive for both Toxin A and
B, and one for B only. No signiﬁcant associations were seen between the presence
of CD and number of inpatient days, total duration of antibiotic therapy over the
previous 3 years, PPI use, gender, genotype, FEV1 or macrolide use. There was
a trending relationship (p = 0.131) between intravenous antibiotic (IVAB) courses
received in the previous 12 months and the presence of toxigenic CD. In CF patients,
disease-causing ribotypes included 014, 002, and 078 with 20% positive for 001,
a ribotype commonly associated with CD associated disease (CDAD). No disease-
causing ribotypes were seen in our controls.
This is the largest study of CD in CF and reports the highest prevalence (50%)
to date. This is the ﬁrst study to report ribotypes. Despite toxin positivity and
ribotypes associated with CDAD all patients were asymptomatic. The relationship
with IVABs needs further investigation.
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Objectives: To evaluate a commercial Lactobacillus reuteri probiotic versus placebo
in the gastrointestinal health of cystic ﬁbrosis (CF) patients, their effect in the fat
absorption and their inﬂuence in the gut microbiota.
Methods: A total of 33 CF-patients (23 males and 10 females, age range: 8−44)
from 3 Spanish Hospitals were enrolled. Patients were randomized in Group A
(6 months of probiotic followed by 6 months of placebo) or Group B (6 months
of placebo followed by 6 months of probiotic). GIQLI (gastrointestinal) and SF-36
(general) health questionnaires were done at basal visit (1), after probiotic (2)
and placebo (3) intakes. Fecal samples were also collected for fat absorption,
calprotectin quantiﬁcation and inﬂammatory interleukins. Total fecal DNA was
obtained and a metagenomic 454 pyrosequencing approach was developed to
analyze the microbiome composition.
Results: Our CF-patients related a good tolerance to L. reuteri without sec-
ondary effects. Statistical analysis demonstrated a signiﬁcant improvement of the
gastrointestinal health, signiﬁcant decrease in the calprotectin levels (from 0.75
to 0.64mg/L) and the IL-1b interleukin (from 28 to 40 pg/ml) after probiotic
consumption. Metagenomic results showed that probiotic promoted a reduction in
the total load but with higher bacterial diversity. Signiﬁcant changes were detected
in the Actinobacteria, Firmicutes, and Bacteroidetes phylum, whereas Proteobacteria
density remained stable.
Conclusions: Lactobacillus reuteri consumption in CF-patient enhanced digestive
comfort, decrease the inﬂammation and the bacterial load with signiﬁcant changes
in their microbiota.
